A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls
- PMID: 3689632
- PMCID: PMC1386316
- DOI: 10.1111/j.1365-2125.1987.tb03207.x
A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls
Abstract
1 Six male patients with alcoholic cirrhosis and seven normal control subjects were each given 80 mg twice daily of conventional propranolol for 1 week and 160 mg once daily of a long acting preparation (LA) of propranolol for 1 week. 2 Plasma propranolol levels were measured at regular intervals on the first and seventh days of both weeks and also following an acute intravenous infusion of 10 mg propranolol on a separate occasion. 3 After the single intravenous dose the elimination half-life tended to be prolonged in the cirrhotic group (median 7.15 h) compared with controls (median 2.92 h) (P = 0.055). 4 After multiple oral dosing with 80 mg twice daily of conventional propranolol the steady-state plasma concentration (Css), area under the curve (AUC tau), peak concentration (Cmax) and trough concentration (Cmin) were significantly higher in cirrhotic patients and the peak: trough ratio (Cmax/Cmin) was significantly lower than controls. 5 After multiple oral dosing with 160 mg LA once daily Cmin was significantly higher than Cmax/min significantly lower in cirrhotic patients; Css, AUC and Cmax were higher than controls but not statistically different. 6 Within both subject groups the bioavailability of 80 mg twice daily of conventional propranolol tended to be greater than 160 mg LA once daily. Cmax was significantly higher in both groups and Css higher in the cirrhotic group with conventional propranolol. 7 In the cirrhotic group the mean reduction in supine heart rate in the steady state was 31.8% with conventional 80 mg twice daily propranolol and 23.75% with 160 mg LA once daily.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol.Arzneimittelforschung. 1984;34(4):507-12. Arzneimittelforschung. 1984. PMID: 6378211 Clinical Trial.
-
The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension.Br J Clin Pharmacol. 1983 May;15(5):519-27. doi: 10.1111/j.1365-2125.1983.tb02085.x. Br J Clin Pharmacol. 1983. PMID: 6860527 Free PMC article. Clinical Trial.
-
Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol.J Clin Pharmacol. 1987 May-Jun;27(5):390-6. doi: 10.1002/j.1552-4604.1987.tb03036.x. J Clin Pharmacol. 1987. PMID: 3693583 Clinical Trial.
-
Pharmacokinetics of long acting propranolol. Implications for therapeutic use.Clin Pharmacokinet. 1987 Jul;13(1):51-64. doi: 10.2165/00003088-198713010-00003. Clin Pharmacokinet. 1987. PMID: 3304770 Review.
-
Clinical pharmacokinetics of mizolastine.Clin Pharmacokinet. 2001;40(7):501-7. doi: 10.2165/00003088-200140070-00002. Clin Pharmacokinet. 2001. PMID: 11510627 Review.
Cited by
-
Systemic exposure to propranolol in patients with chronic liver disease and its correlation with portal blood flow.Front Med (Lausanne). 2022 Sep 21;9:973606. doi: 10.3389/fmed.2022.973606. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36213672 Free PMC article.
-
Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.Clin Pharmacokinet. 1991 Jan;20(1):1-14. doi: 10.2165/00003088-199120010-00001. Clin Pharmacokinet. 1991. PMID: 2029799 Review. No abstract available.
-
Individual variation in first-pass metabolism.Clin Pharmacokinet. 1993 Oct;25(4):300-28. doi: 10.2165/00003088-199325040-00005. Clin Pharmacokinet. 1993. PMID: 8261714 Review.
-
Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.CNS Drugs. 2017 May;31(5):389-403. doi: 10.1007/s40263-017-0430-3. CNS Drugs. 2017. PMID: 28405886 Review.
-
Safety of propranolol in portal hypertension. Conventional and long acting formulations.Drugs. 1989;37 Suppl 2:70-3; discussion 74-6. doi: 10.2165/00003495-198900372-00013. Drugs. 1989. PMID: 2680433 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical